FDA Can Now Ask the Public for OTC Monograph Data

FDA published a procedure on 16 July 2026 for how it will ask the public for data to inform changes to over-the-counter drug monographs. The notice is barely two pages and creates no obligation on anyone. But it fills in a step the OTC monograph system had left implicit — how, concretely, the agency gathers the evidence it needs when it wants to change a monograph on its own initiative rather than waiting for industry to bring it a request.

The monograph system, briefly

OTC monograph drugs — the sunscreens, antacids, antihistamines, and cough medicines sold without an approved application — are regulated under section 505G of the FD&C Act, the framework the CARES Act created in 2020. A monograph, issued as a final administrative order, sets the conditions under which drugs in a therapeutic category are generally recognised as safe and effective: the active ingredients, uses, doses, routes, labeling, and testing. Those conditions can be amended, revoked, or otherwise modified by a further order under section 505G(b) — and, importantly, either FDA or an outside requestor can start that process. A requestor moves the agency by filing an OTC monograph order request; FDA, this notice makes explicit, can move on its own.

That is the gap the notice addresses. When FDA itself wants to modify a monograph — to add a generally-recognised condition, say — it needs the underlying data, and much of that data sits with manufacturers and researchers rather than inside the agency. The Data Request is the instrument for asking.

How a Data Request will work

The mechanics are deliberately routine, which is the point — a predictable channel is easier to watch and to answer than an ad hoc one.

• Where. FDA will announce each Data Request on the OTC Monographs@FDA portal, not by individual Federal Register notice, so the portal becomes the place to watch.
• What it will contain. Instructions for submitting the data and information, including how to handle confidential information, and how submissions may be viewed by the public.
• How to keep up. Interested parties can sign up for FDA email mailing lists on the portal to be alerted when a Data Request — or other monograph activity — is announced.
• Advance warning. Planned Data Requests of this type will be listed in FDA’s Annual Forecast for Planned Monograph Activities, the nonbinding list of what the agency intends to initiate over the coming three years.

What it is not

For once the boundaries are as informative as the substance, and FDA drew them carefully. A Data Request is not a proposed order and carries no binding force; the notice announcing the process has no comment period of its own. It is explicitly separate from the process FDA will use to request data packages to support GRASE finalisations under section 505G(a)(3), which the agency says it will announce in a future notice. It does not cover the test-methods crowdsourcing described in the OMUFA II commitment letter, nor the data a requestor submits inside its own order request, nor the statutory public-comment periods that attach to a proposed order or an interim final order under section 505G(b).

In other words, this is the front end of a longer machine. The leverage is real but indirect: FDA can now put out a structured, portal-based call for evidence to build the record for a change it wants to make — and the binding decision, with its comment rights intact, still comes later. It arrived the same week FDA finalised its guidance on formal meetings for OTC monograph drugs, another piece of the section 505G apparatus being filled in under the program’s November 2025 reauthorization.